TABLE 2.

IgG GMVs against PT, FHA, PRN, and FIM 2/3 in Swedish study participants, assorted by vaccine group and analyzed by illness severity

Vaccine groupAntigenGMV, EU/mlP value
Less severe illnessaTypical illnessa
DTPT311.3372.80.53
FHA58.9115.00.18
PRN2.66.20.16
FIM 2/36.27.80.71
DTaP-2PT74.7127.60.06
FHA298.1432.30.28
PRN0.61.70.02
FIM 2/32.52.40.95
DTaP-5PT76.8204.60.06
FHA84.1204.20.22
PRN135.7435.40.05
FIM 2/3304.9709.30.15
DTwPPT313.0304.70.94
FHA294.8295.60.10
PRN103.866.70.56
FIM 2/3228.386.40.24
  • a Typical, criteria established by an ad hoc committee from WHO, which required at least 21 consecutive days of paroxysmal cough and a positive culture for B. pertussis, a significant increase in IgA or IgG antibody to PT, FHA, or FIM, or a culture-confirmed household contact (26); less severe, laboratory confirmation or culture-confirmed household contact but with cough illness that did not include 21 consecutive days of paroxysmal cough. For the DT group, 12 subjects had less severe symptoms and 41 had typical symptoms; for the DTaP-2 group, 15 subjects had less severe symptoms and 22 had typical symptoms; for the DTaP-5 group, 6 subjects had less severe symptoms and 7 had typical symptoms; and for the DTwP group, 10 subjects had less severe symptoms and 23 had typical symptoms.